Reduction in Left Ventricular Messenger RNA for Transforming Growth Factor β 1 Attenuates Left Ventricular Fibrosis and Improves Survival Without Lowering Blood Pressure in the Hypertensive TGR(mRen2)27 Rat
- 1 November 2000
- journal article
- other
- Published by Wolters Kluwer Health in Hypertension
- Vol. 36 (5) , 747-754
- https://doi.org/10.1161/01.hyp.36.5.747
Abstract
—Angiotensin II recruits transforming growth factor β 1 (TGFβ 1 ) and is related to left ventricular fibrosis. However, it is unclear whether chronic in vivo reduction in left ventricular TGFβ 1 expression blunts fibrosis and improves outcome in angiotensin II–dependent hypertension. Four-week-old male hypertensive TGR(mRen2)27 (Ren2) rats received either normal food, low-dose losartan (0.5 mg · kg −1 · d −1 ), or tranilast (a nonspecific TGFβ inhibitor; 400 mg · kg −1 · d −1 ) (n=10 for each group) for 12 weeks and were compared with Sprague-Dawley control rats. The effect of tranilast on survival was evaluated in 34 additional untreated homozygous Ren2 rats. Tranilast or low-dose losartan did not lower blood pressure. However, the increase in left ventricular weight (Ren2 versus SD 3.1±0.16 versus 2.1± 0.06 mg/g body wt; P P 1 mRNA and fibronectin mRNA and blunted the increase in hydroxyproline content and the increase in perivascular fibrosis. The perivascular fibrosis score correlated significantly with the level of expression of TGFβ 1 ( r =0.62; P =0.019). In situ hybridization demonstrated increases in TGFβ 1 mRNA, predominantly in perivascular and nonmyocyte areas. Both drugs did not prevent the decrease in systolic or diastolic dP/dt, but tranilast significantly improved the survival of untreated Ren2 rats ( P =0.029). In conclusion, TGFβ 1 mRNA expression is increased predominantly in nonmyocyte regions in the hypertrophied left ventricle in this angiotensin II–dependent model of hypertension. This increase is probably due to high angiotensin II levels rather than to hypertension. This is the first study to suggest that chronic inhibition of TGFβ 1 expression attenuates left ventricular hypertrophy and fibrosis, even without lowering blood pressure.Keywords
This publication has 23 references indexed in Scilit:
- Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-β1 and endothelin-1 from fibroblastsCardiovascular Research, 1998
- Inhibitory effects of tranilast on expression of transforming growth factor-β isoforms and receptors in injured arteriesAtherosclerosis, 1998
- Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and β‐adrenergic neuroeffector mechanisms in transgenic (mREN2)27 ratsBritish Journal of Pharmacology, 1998
- Differential Protein Expression and Subcellular Distribution of TGFβ1,β2andβ3in Cardiomyocytes During Pressure Overload-induced HypertrophyJournal of Molecular and Cellular Cardiology, 1997
- Inhibitory Effect of Tranilast on Activation and Transforming Growth Factor β1 Expression in Cultured Rat Stellate CellsBiochemical and Biophysical Research Communications, 1996
- Tranilast Suppresses Intimal Hyperplasia in the Balloon Injury Model and Cuff Treatment Model in RabbitsThe Japanese Journal of Pharmacology, 1996
- Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin???angiotensin-system gene expression and cardiovascular functionsJournal Of Hypertension, 1995
- Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression.Hypertension, 1994
- Increased EGF binding and EGFR mRNA expression in rat aorta with chronic administration of pressor angiotensin IIBiochemical Medicine and Metabolic Biology, 1992
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyNew England Journal of Medicine, 1990